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The PH domain leucine-rich repeat protein phosphatase,
PHLPP, plays a central role in controlling the amplitude of
growth factor signaling by directly dephosphorylating and
thereby inactivating Akt. The cellular levels of PHLPP1 have
recently been shown to be enhanced by its substrate, activated
Akt, via modulation of a phosphodegron recognized by the E3
ligase -TrCP1, thus providing a negative feedback loop to
tightly control cellular Akt output. Here we show that this feed-
back loop is lost in aggressive glioblastoma but not less aggres-
sive astrocytoma. Overexpression and pharmacological studies
reveal that loss of the feedback loopdoes not result fromadefect
in PHLPP1 protein or in the upstream kinases that control its
phosphodegron. Rather, the defect arises from altered localiza-
tion of -TrCP1; in astrocytoma cell lines and in normal brain
tissue the E3 ligase is predominantly cytoplasmic, whereas in
glioblastomacell lines andpatient-derived tumorneurospheres,
the E3 ligase is confined to the nucleus and thus spatially sepa-
rated from PHLPP1, which is cytoplasmic. Restoring the local-
ization of -TrCP1 to the cytosol of glioblastoma cells rescues
the ability of Akt to regulate PHLPP1 stability. Additionally, we
show that the degradation of another -TrCP1 substrate,
-catenin, is impaired and accumulates in the cytosol of glio-
blastoma cell lines.Our findings reveal that the cellular localiza-
tion of-TrCP1 is altered in glioblastoma, resulting in dysregu-
lation of PHLPP1 and other substrates such as -catenin.
Glioblastomas (World Health Organization grade IV)
account for 70% of all tumors of the central nervous system
(CNS),making them themost common type ofmalignant brain
tumor (1). Primary glioblastoma, commonly referred to as glio-
blastomamultiforme (GBM),3 accounts for the vast majority of
glioblastoma cases and presents in an acute de novo manner
with no prior evidence of lower grade pathology. Secondary
glioblastomas are less common and are derived from the pro-
gression of lower grade astrocytomas (World Health Organiza-
tion I-III) (2). Loss or dysregulation of a tumor suppressor can
result in the activation of signaling pathways that drive cell
growth, proliferation, and survival and aid tumor initiation and
development (3).
One signal transduction pathway that is important to the
initiation and progression of many cancer types, including
those of the CNS, is the phosphatidylinositol 3-kinase (PI3K)/
Akt pathway. In the presence of proliferative signals, Akt is
activated by phosphorylation at two crucial sites. The first site,
known as the activation loop (Thr-308 on Akt1), is phosphory-
lated by PDK-1 (4). The second site, termed the hydrophobic
motif (Ser-473 on Akt1), is phosphorylated through a mecha-
nism regulated by the TORC2 protein complex (5, 6). Once
activated, Akt phosphorylates defined substrates in the cytosol
and nucleus, ultimately inducing proliferation and anti-apop-
totic signaling pathways (7). Signaling by Akt is terminated by
two primarymechanisms; that is, removal of the activating lipid
secondmessenger by the phosphatase PTEN (phosphatase and
tensin homolog on chromosome ten) (8) and direct dephosphor-
ylation of the kinase by phosphatases, including PHLPP (9, 10).
A second signaling pathway that is often amplified in cancer
is theWnt/-catenin signaling pathway, which primarily func-
tions to regulate cell proliferation and apoptosis. Under basal
conditions, levels of free, cytosolic -catenin are suppressed by
proteasomal degradation. This process is regulated by a protein
complex composed of axin, adenomatous polyposis coli, casein
kinase 1 (CK1), and glycogen synthase kinase-3 (GSK-3) (11).
Accumulation and nuclear translocation of cytosolic -catenin
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activates various oncogenic substrates including c-Myc, cyclin
D1, and members of the AP-1 family (12, 13).
Previous studies have shown that both PI3K/Akt and
-catenin signaling can be up-regulated in tumorigenesis
through a number of mechanisms. In the case of Akt, these
include gene amplification or gain of function mutations in
upstream receptor tyrosine kinase and hormone receptors (the
most common mechanism in CNS tumors), activating muta-
tions in PI3K, or loss of function mutations in the regulatory
phosphatase PTEN (14–17). In the case of-catenin, activation
can result from amplification of upstream components of the
Wnt pathway such as Dishevelled as well as mutations to
-catenin itself and regulatory proteins such as adenomatous
polyposis coli and axin (18–20). However, these mechanisms
alone do not account for all instances where these signaling
pathways are constitutively active in tumors, suggesting that
alterations in additional proteins is responsible for activation.
The PHLPP phosphatases are members of a novel family of
Ser/Thr phosphatases composed of three isozymes: the alter-
natively spliced PHLPP1 and PHLPP1 and a separate gene
product, PHLPP2 (21). Our laboratory has previously estab-
lished that PHLPP selectively dephosphorylates the hydropho-
bicmotif of Akt and protein kinase C (PKC) isozymes (9, 22). In
the case of Akt, dephosphorylation at this site reduces its
intrinsic catalytic activity, leading to increased apoptosis and
decreased proliferation (9, 10). In the case of PKC, dephosphor-
ylation destabilizes PKC and shunts it to degradation pathways
(22). There is mounting evidence that PHLPP serves as a tumor
suppressor protein in cancer. First, overexpression of PHLPP in
normal or cancer cells decreases proliferation and induces apo-
ptosis in concert with inactivation of Akt signaling. Further-
more, overexpression of PHLPP1 in a glioblastoma cell line
was shown to greatly reduce tumor growth in a nude mouse
model (9). Second, PHLPP1 and PHLPP2 are frequently absent
or reduced in cancer. Notably, PHLPP1mRNAhas been shown
to be reduced by an order of magnitude in chronic lymphocytic
leukemia (CLL) (23) and, in fact, was absent in 50% of CLL
tumors in one study (24); PHLPP1 and PHLPP2 mRNA levels
were found to be 5- and 4-fold lower, respectively, in esophageal
adenocarcinomas (25), and several studies have identified sig-
nificant reduction in PHLPP1 and PHLPP2 mRNA in colon
cancer (26–28). PHLPP1 mRNA has also been shown to be
2-fold lower in glioblastoma (29), melanoma (30), and breast
carcinomas (31, 32). Additionally, PHLPP1 protein levels are
reduced in cancers of the liver, pancreas, and stomach (33).
Furthermore, PHLPP1 and PHLPP2 protein expression is sig-
nificantly decreased or lost in 78 and 86%, respectively, of colon
tumors (34). Thus, reductions in PHLPP accompany a broad
spectrum of cancers, consistent with loss of PHLPP conferring
a survival advantage to cancer cells. Indeed, PHLPP is deleted as
often as PTEN (40%) in metastatic prostate cancers (35).
Aberrations in PHLPP may be particularly prevalent in glio-
blastoma, where several mutations have been found in human
tumors and where higher levels of PHLPP correlate with higher
survival rates (36, 37). These findings suggest that maintenance
of PHLPP levels is important for inhibition of tumor growth,
and mechanisms that control the amount of PHLPP in the cell
are often lost in tumorigenesis.
Ubiquitin-mediated degradation is important for the proper
regulation of many cellular processes including transcription
and cell cycle progression. E3 ubiquitin protein ligases confer
the specificity of this system by binding and targeting certain
substrates for ubiquitination. The levels of E3 ligases can dra-
matically alter signal transduction pathways involved in tumor-
igenesis by influencing the levels of their substrate (38). One
such E3 ligase family, -transducin repeat containing proteins
(-TrCPs), are F-box proteins that recognize phosphorylated
serine residues of target substrates that are processed by the
ubiquitin/proteasome pathway (39, 40). -TrCP1 has been
demonstrated to mediate the phosphorylation-dependent deg-
radation of numerous proteins involved in tumorigenesis, the
most well studied being -catenin (41, 42) and IB (43).
Recently, -TrCP1 was identified as the E3 ligase responsible
for ubiquitin-mediated degradation of PHLPP1 in a phospho-
rylation-dependentmanner (44). Similar to-catenin, PHLPP1
is directly phosphorylated by CK1 and GSK-3 on multiple
serine residues to create a phosphodegronmotif.-TrCP1 then
binds PHLPP1 through recognition of this destruction motif,
and PHLPP1 is subsequently polyubiquitinated and then
degraded by the proteasome (44). Phosphorylation of GSK-3
by Akt inhibits its activity and thus directly influences the sta-
bility of PHLPP1; this results in a feedback loop through which
active Akt stabilizes its negative regulator, PHLPP1, ultimately
serving to dampen Akt signaling.
Here we identify a subset of tumors in which the negative
feedback loop by which the level of active Akt determines the
expression of its negative regulator PHLPP1 is lost. Specifically,
we have found that this feedback loop is broken in high grade
glioblastomas because of the confinement of -TrCP1 to the
nuclear compartment, where it can no longer target its cytoso-
lic substrates for degradation, providing a novel mechanism for
the dysregulation of PHLPP1 and -catenin levels.
EXPERIMENTAL PROCEDURES
Plasmids—HA-PHLPP1 has been previously described (9).
The additional 1536 base pairs of PHLPP1 were amplified
by OneStep RT-PCR (Qiagen) from RNA isolated from
human brain and subcloned into the HA-PHLPP1 vector
to generate the full-length PHLPP1 gene product
(NM_194449) (21). RFP-PHLPP1 was constructed by PCR
amplification and subsequent cloning into a pcDNA3 vector
with monomeric RFP as an N-terminal tag. Myc-epitope
tagged -TrCP1 was purchased from Addgene and has been
described previously (45). -TrCP1 was subcloned in-frame
C-terminal to CFP in pcDNA3 vector using Gateway cloning
techniques (Invitrogen).
Materials and Antibodies—Cycloheximide, LY294002,
GSK3 inhibitor IX (GSK3i IX), and MG-132 were purchased
fromCalbiochem and dissolved in dimethyl sulfoxide (DMSO).
Antibodies to PHLPP1 and PHLPP2 were purchased from
Bethyl Laboratory. The following antibodies were purchased
from Cell Signaling: phospho-antibodies for Thr-308 (P308)
and Ser-473 (P473) of Akt, phospho-GSK-3/ (Ser-21/9),
phospho-glycogen synthase (Ser-641), phospho--catenin
(Ser-45), and total Akt Antibody. An anti-HAmonoclonal anti-
body was purchased from Covance. A DsRed (anti-RFP) anti-
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body was purchased from Clontech. A -TrCP1-specific anti-
bodywas purchased from Invitrogen.Monoclonal antibodies to
actin and Myc were purchased from Sigma. Antibodies to
annexin 1, lamin A, and -catenin were purchased from Santa
Cruz Biotechnology. The antibody to voltage-dependent anion
channel protein (VDAC) was obtained from Affinity BioRe-
agents. Ultra-link protein A/G beads were obtained from
Thermo Scientific. All other materials and chemicals were rea-
gent grade. Non-viable cell pellets from the NCI60 panel of
tumor cell lines were provided by the Developmental Thera-
peutics Program (NCI/National Institutes of Health).
Cell Transfection and Immunoblotting—SNB-75, SF-268,
SF-295, SF-539, SNB-19, U251, and H157 cell lines were main-
tained in RPMI (Cellgro) containing 10% FBS (Hyclone) and 1%
penicillin/streptomycin at 37 °C in 5%CO2. Transient transfec-
tion of all cell lines was carried out using jetPRIME transfection
reagent (Polyplus Transfection) following the manufacturer’s
protocol. For immunoblotting, cultured cells and non-viable
cell pellets were lysed in buffer A (50 mM Na2HPO4, 1 mM
sodium pyrophosphate, 20mMNaF, 2 mM EDTA, 2mM EGTA,
1% Triton X-100, 1mMDTT, 200M benzamidine, 40gml1
leupeptin, and 1 mM PMSF, pH 7.4) and sonicated for 5s, and
protein yieldwas determined using theCoomassie BCAprotein
assay (Pierce). Lysates containing equal protein were analyzed
by SDS-PAGE, and individual blots were probed using the indi-
cated antibody. Densitometric analysis was performed with
AlphaView analysis software (Version 1.3.0.6) by Alpha Inno-
tech Corp.
Cellular Ubiquitination Assays—H157 cells were transfected
with DNA encoding RFP-PHLPP1 (1 g) and HA-ubiquitin
(0.5g). Cells were pretreated for 30minwithMG-132 (10M)
before the addition of LY294002 (20 M) or DMSO for the
indicated times before harvest with immunoprecipitation
buffer (50mMTris-HCl, pH 7.4, 100mMNaCl, 5mMEDTA, 1%
Triton X-100, 10 mM sodium pyrophosphate, 1 mM phenyl-
methylsulfonyl fluoride, 1 mM sodium vanadate, and 10 mM
N-ethylmaleimide to preserve the ubiquitinated species). Ten
percent of the total detergent-solubilized cell lysate was
quenched in SDS sample buffer for further analysis, and the
remaining lysate was cleared by centrifugation at 13,000 g for
5 min. For immunoprecipitation, the supernatants were incu-
bated with DsRed (anti-RFP) antibody overnight at 4 °C and
then with Ultra-link protein A/G beads for and additional 2 h.
The immunocomplexes were washed three times with immu-
noprecipitation buffer, and proteins were separated by SDS-
PAGE and analyzed by immunoblotting.
Cellular Fractionation—Tissue samples fromhealthy human
brain (case numbers 1505 and 1530) were homogenized at low
speed and fractionated using the Qproteome Cell Compart-
ment kit (Qiagen) according to the manufacturer’s protocol.
Astrocytoma, glioblastoma, and patient-derived glioblastoma
tumor neurosphere cell lines were fractionated by centrifuga-
tion as follows. Approximately 1 106 cells were lysed in 200l
of hypotonic lysis buffer B (10 mM Tris-HCl, pH 7.5, 50 mM
NaCl, 1 mM sodium pyrophosphate, 20 mM NaF, 200 M benz-
amidine, 40 g/ml leupeptin, 1 mM PMSF, and 2 mM sodium
vanadate). Lysates were passed through a 25-gauge needle 12
times, and a portion of the lysate was retained; the remainder
was centrifuged at 800 g for 5min at 4 °C to pellet the nuclear
material. The nuclear pellet was then resuspended in 100 l of
buffer C (buffer B  1% Triton X-100), mixed by vortex, and
placed on ice for 10 min before centrifugation at 16,000 g for
15 min. The resulting supernatant was collected as the nuclear
fraction. The supernatant taken after isolation of the nuclear
pellet was subjected to centrifugation for 20min at 110,000 g.
The resulting supernatant was collected as the cytosolic frac-
tion. The remaining pellet was resuspended in 100 l of buffer
C, mixed by vortex, and placed on ice for 10 min before centri-
fugation at 110,000  g for 20 min. The resulting supernatant
was collected as the membrane fraction. The remaining pellet
was resuspended in 100 l of buffer C and collected as the
detergent-insoluble pellet. An equal volume of each fraction
was run on an SDS-PAGE gel and analyzed by immunoblotting.
Generation of Neurospheres—Eligible patients were those
undergoing craniotomy for therapeutic management of a brain
tumor. Written informed consent was obtained from all
patients. The studywas approved by the Lothian (Scotland,UK)
regional ethics committee (LREC 2004/4/16). Tumor biopsies
were processed within 1 h. Cell lines were expanded from glio-
mas as described previously (46, 47). Briefly, tissue was homog-
enized and trypsinized. The single cell suspension was pelleted
then resuspended in expansion media (Advanced DMEM:F-12
(1:1), 1% B27 (10), 0.5%N2 (100), 1% 100mMGlutamax, 1%
penicillin-streptomycin, 1% Fungizone, 10 ng/ml EGF (R&D
Systems, Abingdon, UK), 10 ng/ml basic fibroblast growth fac-
tor (R&D Systems), 5 g/ml heparin (Sigma)), in a Matrigel-
coated (BD Biosciences) flask. All reagents and products are
from Invitrogen unless otherwise stated. Experiments were
performed on low passage number cells (less than passage 10).
Patient-derived neurosphere cell lines (named O, U, and P)
were designated GBM1, GBM2, and GBM3, respectively, and
two additional neurosphere cell lines (TS600 and TS576) have
been described previously (48).
RESULTS
Akt-mediated Enhancement of PHLPP1 Is Preferentially Lost
in Glioblastoma—The frequent elevation of Akt activity in can-
cer, often via unexplained mechanisms, led us to explore
whether the feedback loop between Akt and PHLPP1 is lost in
certain tumors. To this end we compared the activity of Akt,
assessed via the phosphorylation state of Thr-308, with the lev-
els of PHLPP1 in the NCI60 panel of tumor cell lines (Fig. 1a).
Based on the enhancement of PHLPP1 levels by activeAkt (thus
creating a feedback loop to suppress Akt activity) (44), PHLPP1
levels were predicted to track with Akt activity in cell lines con-
taining an intact feedback loop. However, in cells where this
feedback loop is broken, an inverse correlation between
PHLPP1 levels and Akt activity would be expected. The West-
ern blots in Fig. 1a present the levels of PHLPP14 and PHLPP2,
the phosphorylation state of Akt on Thr-308 and Ser-473, and
the relative amount ofAkt in lysates fromeach of theNCI60 cell
lines. The first lane of each gel was loadedwith an equal amount
4 This is the first reportedcloningof thehumanPHLPP1 isoform; throughout
this study, PHLPP1 refers to PHLPP1 because it is the predominant iso-
form expressed in all cell lines examined.
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of lysate fromCOS7 cells overexpressing PHLPP1 to serve as an
internal control for differences in exposure between immuno-
blots. To compare the level of PHLPP1 to Akt activity in each
cell line, we plotted the ratio of PHLPP1 to Thr-308 phosphor-
ylation (Fig. 1b). Note that the phosphorylation of Akt on Thr-
308 was chosen to represent Akt activity because phospho-Ser-
473 is a direct substrate of PHLPP and could potentially be
regulated by the feedback loop described here or be elevated
because of a cellular defect in PHLPP itself. However, in most
cases, the relative amount of phospho-Thr-308mirrored that of
phospho-Ser-473.We identified 5 tumor cell lines (indicated by
asterisks in Fig. 1b) in which the ratio of PHLPP1:Akt (Thr-308)
was at least 1 S.D. below the median value (2 1) of all 60 cell
lines. These tumor cells have low levels of PHLPP1 despite very
high basal Akt activity, consistent with potential loss of the
Akt-mediated feedback loop on PHLPP1. Four of the five iden-
tified cell lines are defined as glioblastomas (SF-295 (number
56), SF-539 (number 57), SNB-19 (number 58), and U251
(number 60); designated cell line numbers are listed in supple-
mental Table 1), and the other is an adenocarcinoma derived
from a renal tumor (786–0 (number 16)). Interestingly, the
four CNS cell lines with a low PHLPP1:Akt (Thr-308) ratio
(numbers 56, 57, 58, and 60) are all classified as glioblastomas,
whereas the twoCNS lines predicted to have an intact feedback
loop (numbers 55 and 59) are less aggressive astrocytomas.
If the feedback loop is lost in the candidate glioblastoma cell
lines with elevated Akt activity and low PHLPP1 expression
(Fig. 1b), we reasoned that Akt activity would no longer affect
the stability of PHLPP1 in these cell lines. However, in the less
aggressive astrocytoma cell lines in which the ratio of PHLPP1
toAkt (Thr-308)would indicate that the feedback loop is intact,
PHLPP1 levels would be expected to retain sensitivity to phar-
macological manipulation of Akt activity. To test this hypoth-
esis, we treated both astrocytoma cell lines and the four candi-
date glioblastoma cell lines with DMSO or a PI3K inhibitor
(LY294002) for 24 h and then analyzed PHLPP1 levels. Fig. 1c
reveals that LY294002 effectively decreased the steady-state
levels of PHLPP1 by 50% in both astrocytoma cell lines (e.g.
compare lanes 1 and 2) but had no significant effect on the
steady-state levels of PHLPP1 in the glioblastoma cell lines
tested (e.g. compare lanes 5 and 6). Thus, we have identified a
subset of aggressive CNS tumors that have lost Akt-mediated
control on the stability of PHLPP1, a key regulatorymechanism
for homeostasis of the Akt signaling output.
Loss of the Feedback Loop in Glioblastoma Is Independent of
PHLPP1, CK1, and GSK-3—As previously reported (44), the
effects of Akt activity on PHLPP1 stability are mediated
through GSK-3-dependent phosphorylation of PHLPP1, re-
sulting in its ubiquitination and proteasome-mediated degra-
dation. Consistent with this mechanism, inhibition of PI3K by
LY294002 caused a robust increase in the ubiquitination of
PHLPP1 (supplemental Fig. 1), whereas inhibition of GSK-3 or
the proteasome prevented the LY294002-induced reduction in
PHLPP1 steady-state levels (supplemental Fig. 2).
To determine whether a defect in PHLPP1 itself is responsi-
ble for the loss of Akt-mediated regulation of its stability, we
monitored the stability of an exogenously expressed construct
of PHLPP1 in response to PI3K inhibition. HA-tagged PHLPP1
was transfected into an astrocytoma cell line (SF-268) and sev-
eral of the candidate glioblastoma cell lines (SF-295, SNB-19,
U251) for 24 h before treatment with DMSO or LY294002 for
24 h; anti-HA antibodywas used tomonitor levels of exogenous
PHLPP1 (Fig. 2a). The activity of Akt was effectively blocked by
treatment with LY294002 in all cell lines, as indicated by the
reduced phosphorylation of Akt (Ser-473). Similar to endoge-
nous PHLPP1 in the astrocytoma cell line containing an intact
feedback loop, exogenous PHLPP1 levels in these cellswere also
significantly reduced after Akt inhibition (compare lanes 1 and
2). However, the level of exogenous PHLPP1 was refractory to
Akt inhibition in all three of the glioblastoma lines, which har-
bor a broken feedback loop (e.g. compare lanes 3 and 4). The
inability to rescue the defect by overexpression of exogenous
PHLPP1 reveals the loss of Akt-mediated regulation of PHLPP1
in glioblastoma is not caused by a defect in PHLPP1 itself.
We next sequentially investigated the functionality of each
player involved in the described phosphorylation-dependent
degradation pathway from Akt to PHLPP1 to identify at which
step the loop is broken in the indicated glioblastoma cell lines
(Fig. 2b). First, we tested whether Akt activity was being effec-
tively blocked by inhibition of PI3K in glioblastomas and astro-
cytomas. In addition to loss of phosphorylation at Ser-473,
phosphorylation of anAkt substrate, GSK-3/ (Ser-21/9), was
reduced in response to Akt inhibition by similar amounts in
both astrocytoma (compare lanes 1 and 2) and glioblastoma cell
lines (e.g. compare lanes 3 and 4). These data demonstrate that
inhibition of PI3K is able to decrease Akt activity in both astro-
cytoma and glioblastoma cells (Fig. 2b). Second, we tested
whether GSK-3 is able to properly phosphorylate its sub-
strates in cells with a broken feedback loop. To this end, we
examined the phosphorylation state of glycogen synthase, an
established target of GSK-3, after 24 h of PI3K inhibition.
After relief of the Akt-mediated inhibition of GSK-3, phos-
phorylation of glycogen synthase (Ser-641) was increased in
both glioblastoma and astrocytoma cell lines, indicating that
GSK-3 is functional toward its substrates (Fig. 2b). Third, we
investigated whether CK1 is able to phosphorylate its sub-
strates in glioblastoma. The stability of a well documented CK1
substrate, -catenin, is regulated in amanner analogous to that
FIGURE 1.Akt-mediated feedback loop enhancing PHLPP1 levels is preferentially lost in CNS tumors. A, lysates of non-viable cell pellets from the NCI60
panel of tumor cell lines (NSCLC, non-small cell lung cancer; PC, prostate cancer; CNS, central nervous system) were analyzed byWestern blotting for PHLPP1,
PHLPP2, Akt phosphorylation on Thr-308 (P308) or Ser-473 (P473), Akt, and actin. The first lane in each gel (C) contains equal lysate from COS7 cells overex-
pressing PHLPP1 and serves to control for differences in exposure among different blots. B, the ratio of PHLPP1 to active Akt (Thr-308) was obtained by
densitometric analysis of theblots ina andplotted across thepanel of 60 cell lines.Horizontal lines indicate the valueof themedian (top line) andoneS.D. below
the median value (bottom line). Cell lines with a ratio less than 1 S.D. below the median line are indicated by an asterisk. C, the indicated CNS cell lines were
treated for 24 h with DMSO (D) or LY294002 (LY) (20 M) and PHLPP1, Akt phosphorylation on Thr-308 (P308) or Ser-473 (P473), and actin were detected by
Western blot analysis. The relative amount of PHLPP1, normalized to actin, is shown in the graph; data represent the mean  S.E. of three independent
experiments.
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of PHLPP1, where a constitutive “priming” phosphorylation by
CK1 is necessary for subsequent phosphorylation within the
phosphodegron motif. Therefore, to determine whether CK1
is functional in glioblastoma, we probed the CK1 site on
-catenin (Ser-45) with a phospho-specific antibody. We ob-
served a basal level of-catenin (Ser-45) phosphorylation in all
of the cell lines tested, indicating that CK1 is functional in
both intact and broken loop cell lines (Fig. 2b). Taken
together, these data indicate that loss of Akt-mediated reg-
ulation of PHLPP1 stability does not result from a defect in
PHLPP1 or the kinases responsible for phosphorylating and
promoting its degradation.
-TrCP1 Is Confined to the Nucleus in Glioblastoma Cell
Lines and Patient Samples—Having established that the up-
stream kinases responsible for regulation of PHLPP1 stability
are functional, we next asked whether a defect in the E3 ligase
and/or proteasomal degradation machinery could be responsi-
ble for the broken feedback loop in glioblastoma. One possible
mechanism for the loss of Akt-mediated regulation of PHLPP1
in glioblastoma is that the cellular localization of PHLPP1 or its
E3 ligase, -TrCP1, could be altered in these cells. To examine
the localization of these proteins, astrocytoma and glioblas-
toma cell lines were lysed, and the membrane, cytoplasmic,
nuclear, and detergent-insoluble fractions were isolated. Equal
portions of starting material were then analyzed by immuno-
blotting to determine the subcellular location of PHLPP1 and
-TrCP1. To verify that we effectively isolated the indicated
cellular fractions, antibodies specific to proteins that reside in
each fraction were used as a control (Fig. 3a). Although the
fractionation was clean for the most part, we did observe some
contamination between our nuclear and membrane fractions,
as revealed by the presence of lamin A, a nuclear protein, in the
membrane fraction. However, it is important to note that there
was no contamination between the cytosolic and nuclear frac-
FIGURE 2. Loss of the feedback loop in glioblastoma is independent of PHLPP1, CK1, and GSK-3. A, astrocytoma and glioblastoma cell lines were
transfected with HA-PHLPP1 for 24 h before 24 h treatment with DMSO or LY294002 (20 M). Immunoblotting was used to determine levels of exogenous
PHLPP1 (HA) aswell as the phosphorylation state of Akt (Ser-473) and actin. The relative amount of exogenousHA-PHLPP1, normalized to actin, is shown in the
graph; data represent themean S.E. of three independent experiments. *, p 0.05 comparedwithDMSO. B, the indicated cell lineswere treatedwithDMSO
or LY294002 (20 M) for 24 h, and immunoblotting was used to determine PHLPP1 levels, the phosphorylation state of Akt (Ser-473), phospho-GSK-3/
(Ser-21/9), phospho-glycogen synthase (Ser-641), and phospho--catenin (Ser-45). Actin was used as a loading control.
FIGURE 3.-TrCP1 is confined to the nucleus in glioblastoma cell lines and patient samples. a, astrocytoma and glioblastoma cell lines were fractionated
asdescribedunder “Experimental Procedures.” Fractions representingequal amountsof cell lysatewere analyzedby immunoblotting todetermine the cellular
location of PHLPP1 and -TrCP1. b, frontal cortex from healthy human brain and patient-derived glioblastoma tumor neurosphere specimens were fraction-
ated as described under “Experimental Procedures.” Fractions were analyzed by immunoblotting to determine the cellular location of PHLPP1 and -TrCP1.
Voltage-dependent anion channel protein (membrane) (VDAC), annexin 1 (cytosol), and lamin A (nucleus) were used as control markers for the indicated
cellular fractions.W, whole cell lysate;M, membrane; C, cytosol; N, nuclear; D, detergent-insoluble pellet.
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tions. Cellular fractionation revealed that PHLPP1 was located
primarily in the cytosol of both astrocytoma and glioblastoma
cells. Strikingly, -TrCP1 was primarily cytosolic in the astro-
cytoma cell lines (Fig. 3a, lanes 3 and 8) but partitioned almost
exclusively in the nuclear fraction of the glioblastoma cells (Fig.
3a, lanes 14, 19, and 24). These data identify a key difference in
the cellular localization of -TrCP1 between cell lines contain-
ing an intact versus broken feedback loop; PHLPP1 and
-TrCP1 are both located in the cytosol of cells harboring an
intact feedback loop, whereas -TrCP1 is confined to the
nucleus, sequestered from PHLPP1, in cells where the feedback
loop is broken. Thus, the impaired degradation of PHLPP1
observed in glioblastoma correlates with altered, nuclear local-
ization of -TrCP1.
To confirm whether our results in cell lines held true in glio-
blastoma, we obtained tissue samples fromhumanswho died of
causes unrelated to CNS tumors (normal brain: frontal cortex,
50% astrocytes) and cell lines derived fromneurospheres gen-
erated from biopsies of human glioblastoma patients (46, 47).
These cells are ideal for studying GBM biology because, unlike
cultured cell lines, their genetic profiles are very similar to pri-
mary gliomas. Tissue from two healthy donors and five patient-
derived glioblastoma tumor neurospheres were homogenized,
and cytoplasmic and nuclear fractions were isolated as de-
scribed under “Experimental Procedures” (Fig. 3b). Strikingly,
-TrCP1 was in the nucleus of cells derived from human glio-
blastoma tumors (n 5; lanes 6, 8, and 10) but in the cytosolic
fraction of normal brain from humans who died of other causes
(n 2; lanes 1 and 2). To verify the efficacy of our fractionation,
annexin 1 and lamin A were used as markers of the cytoplasm
and nucleus, respectively. These data confirm that the cellular
localization of -TrCP1 is altered in glioblastoma as compared
with healthy human brain.
Turnover of PHLPP1 Is Slower in Glioblastoma Compared
with Astrocytoma Cell Lines—The finding that the localization
of -TrCP1 is altered in glioblastoma cell lines led us to ask
whether the basal rate of PHLPP1 turnover (i.e. independently
of Akt inhibition) would be impaired as well in these cells com-
pared with astrocytoma cell lines. SF-268 (intact loop) and
U251 (broken loop) cells were treated with cycloheximide
(CHX), an inhibitor of global protein synthesis, in combination
with DMSO or LY294002, and lysates were collected over a
24-h time course (Fig. 4a). Quantitative analysis (Fig. 4a, bot-
tom) of Western blots (Fig. 4a, top) revealed that under basal
conditions PHLPP1was degraded at a significantly faster rate in
the SF-268 cells (t1⁄2 9.5 0.2 h) compared with the U251 cell
line (t1⁄2  19.5  0.3 h). As expected, inhibition of PI3K/Akt
significantly increased the rate of PHLPP1 turnover in SF-268
cells (t1⁄2 3.1 0.2 h) but had virtually no effect on the rate of
turnover in the U251 glioblastoma cell line (t1⁄2 19.4 0.3 h).
Furthermore, the rate of basal PHLPP1 turnover in U251 cells
was significantly slower than that previously reported, whereas
the half-time of PHLPP1 in SF-268 cells was similar to that
reported for other cell lines and, additionally, was comparable
with that determined for overexpressed PHLPP1 by pulse-
chase analysis (data not shown) (44). These data not only indi-
cate that PHLPP1 stability is insensitive to Akt inhibition in
glioblastoma but that the basal rate of PHLPP1 turnover is also
impaired.
Despite the decreased rate of PHLPP1 turnover in glioblas-
toma compared with astrocytoma cell lines, the absolute levels
of PHLPP1 are similar in both (Fig. 1a). Steady-state levels are
dictated by the rate of biosynthesis and the rate of degradation.
Because the rate of degradation ismarkedly reduced in the glio-
blastoma yet steady-state levels are not significantly increased,
we reasoned that the rate of biosynthesis may be slower. This
led us to examinewhether the PHLPP1mRNA levels differed in
glioblastoma versus astrocytoma cell lines. To this end, we ana-
lyzed data generated from six separate microarray experiments
measured onAffymetrixU95Av2 andU133 arrays (supplemen-
tal Table 2). Raw data from each experiment were normalized
to the level of PHLPP1 mRNA present in the SNB-75 astrocy-
FIGURE 4. PHLPP1 turnover is slower, andmRNA levels are reduced in glioblastoma cell lines. A, SF-268 (astrocytoma) and U251 (glioblastoma) cell lines
were treatedwithDMSOor LY294002 (20M) in addition to cycloheximide (CHX; 5M). Lysateswere collected at the indicated times, and levels of PHLPP1 and
the phosphorylation of Akt on Ser-473 (P473) were monitored byWestern blot analysis. PHLPP1 levels were normalized to actin, which was used as a loading
control. Data from three independent experiments were quantified and fit to an exponential decay to obtain half-times of degradation; points represent the
average S.E. *, p 0.05. B, relative PHLPP1 RNA levels were calculated frommicroarray experiments measured on Affymetrix U95Av2 and U133 arrays, and
normalized to the level observed in SNB-75 cells. Data represent the mean S.E. of six independent experiments.
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toma cell line, and relative mRNA levels from each experiment
were used to calculate the average level of PHLPP1 mRNA in
each cell line. Three of the four glioblastoma cell lines (numbers
56, 57, and 60 in Fig. 1a) have at least 40% lower PHLPP1mRNA
levels compared with those in the astrocytoma cell lines (Fig.
4b). SNB-19 glioblastoma cells have only slightly less PHLPP1
mRNA compared with SNB-75 cells. Consistent with this cell
line having higher PHLPP1 mRNA levels and, thus, a greater
rate of PHLPP1 synthesis, the steady-state levels of PHLPP1 are
40% higher in the SNB-19 cells compared with the other glio-
blastoma cell lines (number 58, Fig. 1a). Taken together, these
data indicate that degradation of PHLPP1 is slower in glioblas-
toma, but steady-state levels of PHLPP1 protein are not signif-
icantly increased because of lower mRNA levels.
Turnover of -Catenin Is Impaired in Glioblastoma Cell
Lines—Because the basal rate of PHLPP1 turnover is impaired
in glioblastoma cell lines, we asked whether other substrates of
-TrCP1 that are known to be degraded primarily in the cytosol
are also stabilized. Previous reports reveal that the level and
activity of one such substrate, -catenin, are frequently en-
hanced in glioblastoma and correlate with increasing tumor
grade and poor patient prognosis (49). Thus, we asked whether
-catenin stability was altered in cell lines where -TrCP1 is
confined to the nucleus. We monitored the rate of degradation
of -catenin in SNB-75 (intact loop) and U251 (broken loop)
cell lines by cycloheximide chase over 24 h. Quantitative anal-
ysis (Fig. 5a, bottom) of Western blots (Fig. 5a, top) revealed
that under basal conditions -catenin was degraded at a signif-
icantly faster rate in the SNB-75 cells comparedwithU251 cells.
These data indicate that the degradation of another -TrCP1
substrate is also impaired in glioblastoma cell lines.
Next, we sought to determine whether the amount of -
catenin in the cytosolic pool is enhanced in glioblastoma cell
lines. Indeed, each of the glioblastoma cell lines examined had
higher levels of total -catenin protein compared with astrocy-
toma cells despite having similar mRNA levels (data not shown
and Fig. 2b, assayed by densitometry). To measure the relative
amount of -catenin present in each cellular compartment,
SNB-75 cells andU251 cells were fractionated as described pre-
viously, and equal portions of starting material were analyzed
byWestern blotting. Cytosolic levels of-cateninwere4-fold
higher in U251 cells compared with SNB-75 cells (Fig. 5b).
Thus, themislocalization of-TrCP1 in glioblastomadecreases
the rate of degradation and leads to accumulation of -catenin
in the cytosol.
Expression of Cytoplasmic -TrCP1 in Glioblastoma Rescues
Akt-mediated Regulation of PHLPP1—The finding that
-TrCP1 is differentially localized in cell lines that have an
intact feedback loop compared with those with a broken feed-
back loop led us to test whether re-introducing -TrCP1 to the
cytoplasm of glioblastoma cells was sufficient to restore the
ability of Akt activity to regulate PHLPP1. First, we examined
the subcellular location of CFP-tagged -TrCP1 to determine
whether the protein partitions to the cytosol when overex-
pressed in glioblastoma cells. Fluorescence microscopy and
biochemical fractionation revealed exogenously expressed
-TrCP1 in both the cytosol and nucleus of all cell lines. A
representative image of U251 glioblastoma cells transfected
with CFP--TrCP1 illustrates that this protein was localized
throughout the cell, with a majority present in the cytosol (Fig.
6a). It is noteworthy that the level of exogenous -TrCP1 was
3-fold higher than the endogenous protein, which may
account for the artificial cytosolic localization observed with
overexpression in glioblastoma (data not shown). To test
whether cytosolic localization of -TrCP1 would rescue the
ability of Akt activity to regulate PHLPP1 levels, both astrocy-
FIGURE 5.-Catenin turnover is impaired in glioblastoma cell lines. A, SNB-75 andU251 cell lines were treatedwith cycloheximide (CHX; 5M), and lysates
were collected over 24 h to monitor the levels of -catenin and actin. -Catenin levels were normalized to actin, and data from three independent experi-
ments were quantified and fit to an exponential decay to obtain half-times of degradation; points represent the average S.E. *, p 0.05. B, SNB-75 andU251
cells were fractionated as described under “Experimental Procedures,” and immunoblotting was used to examine -catenin. Densitometry was used to
determine the relative levels of -catenin in each cellular fraction. The graph represents the average S.E. of three independent experiments. *, p 0.05.W
orWCL, whole cell lysate;M, membrane; C, cytosol; N, nuclear.
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toma and glioblastoma cell lineswere transfectedwith vector or
Myc--TrCP1 for 24 h before treatment with DMSO or
LY294002 for an additional 24 h (Fig. 6b). As expected, treat-
ment with LY294002 significantly decreased PHLPP1 levels in
the astrocytoma cell lines (e.g. compare lane 1 to lane 2). Also,
overexpression of-TrCP1 in cells with an intact feedback loop
led to a modest decrease in the level of PHLPP1 (compare lane
1 and lane 3).Moreover, inhibition of PI3K in combinationwith
overexpression of -TrCP1 reduced PHLPP1 levels below that
observed with either -TrCP1 or LY294002 alone (compare
lanes 2 through 4). Next, focusing on the glioblastoma cell lines,
we verified that treatment with LY294002 alone had no effect
on the stability of PHLPP1 (e.g. compare lanes 9 and 10). How-
ever, overexpression of -TrCP1 alone in cells with a broken
feedback loop resulted in a modest decrease in PHLPP1 levels,
comparablewith that observed in the astrocytoma cell lines (e.g.
compare lanes 9 and 11). Importantly, expression of cytoplas-
mic -TrCP1 in combination with PI3K inhibition in the glio-
blastoma cell lines decreased PHLPP1 protein levels to a similar
extent as that observed in astrocytoma cells under the same
conditions (e.g. compare lanes 3 and 4 to 11 and 12). Therefore,
restoring the cytoplasmic localization of -TrCP1 in glioblas-
toma is sufficient to rescue the defective regulatory feedback
loop from Akt to PHLPP1. Taken together these data indicate
1)-TrCP1must be present in the cytosol to effectively degrade
PHLPP1 and 2) nuclear confinement of -TrCP1 is responsible
for the loss of the feedback loop between Akt and PHLPP1 in
glioblastoma.
DISCUSSION
Tightly controlled regulation of protein biosynthesis and
degradation in multiple signal transduction pathways plays a
central role in maintaining cellular homeostasis. Here we show
that -TrCP1, an E3 ligase crucial to maintaining homeostasis
in the PI3K/Akt andWnt/-catenin signaling pathways, is con-
fined to the nucleus in glioblastoma and thus spatially segre-
gated from, and unable to properly target, cytosolic substrates
for degradation. The altered localization of -TrCP1 in glio-
blastoma uncouples the level of a negative regulator, PHLPP,
from the level of activated substrate, phospho-Akt. Further-
more, we show that the degradation of -catenin, a critical
mediator of cell survival, is also impaired in glioblastoma cell
lines. The finding that -TrCP1 is localized differently in glio-
blastoma versus normal brain tissue is significant because this
E3 ligase controls the levels of several crucial mediators of cell
survival and may contribute to the pathogenesis of glioblas-
toma, a disease for which effective treatment options remain
elusive.
The feedback loop that sets the level of PHLPP1 tomatch the
level of phospho-Akt was identified recently by Gao and co-
workers (44). Specifically, they showed that GSK-3, which is
inhibited by Akt phosphorylation, directly phosphorylates
PHLPP1 to initiate ubiquitination by the SCF-TrCP1 complex
and subsequent degradation of ubiquitinated PHLPP1. Thus,
the level of substrate, phosphorylated Akt, sets the level of
enzyme, PHLPP1; this feed-forward stimulation of its negative
regulator, PHLPP1, serves to inhibit its own activity and thus
maintain homeostasis.We reasoned that disruption of the Akt-
mediated feedback loop on PHLPP1 is a potential mechanism
to promote the constitutive activation of Akt that is common in
cancer. To test this possibility, we examined levels of PHLPP1
and phospho-Akt in tumor lysates from the NCI60 panel of
tumor cell lines to identify candidate lines in which this feed-
back loopmight be broken (Fig. 1a). Consistent with Akt activ-
ity controlling PHLPP1 levels, we observed a modest correla-
tion between the relative levels of basal Akt activity (assessed by
monitoring the phosphorylation of Thr-308) and PHLPP1 pro-
tein levels. Interestingly, this correlation was lost in four of six
CNS tumor cell lines. Furthermore, the loss was associatedwith
tumor grade; the four lines in which PHLPP1:Akt (Thr-308)
ratio was unusually low were from grade IV glioblastomas,
whereas the remaining twoCNS tumor lines, with an average or
above average PHLPP1:Akt (Thr-308) ratio, were derived from
lower grade astrocytomas (Fig. 1b). One possible explanation
for the dramatic divergence between Akt activity and PHLPP1
FIGURE 6. Expression of -TrCP1 in the cytosol rescues Akt-mediated regulation of PHLPP1 in glioblastoma. A, a CFP-tagged construct of -TrCP1 was
expressed in U251 cells. Differential interference contrast (DIC; top) and CFP (middle) images were merged (bottom) to show the cellular localization of exogenous
-TrCP1 in GBM cells. B, Myc--TrCP1was overexpressed in astrocytoma and glioblastoma cell lines for 24 h before 24 h treatmentwith DMSOor LY294002 (20M).
Immunoblottingwasused tomonitor the levelsof exogenousMyc--TrCP1 (Myc), PHLPP1,AktphosphorylationonSer-473 (P473), andactin. The relativeamountof
PHLPP1, normalized to actin, is shown in the graph; data represent themean S.E. of three independent experiments. *, p 0.05.
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levels is that the feedback loop was lost in the cancer cell lines
derived from more aggressive glioblastomas. We tested this by
examining whether PHLPP1 levels were sensitive to inhibition
of PI3K in all of theCNS tumor cell lines. Indeed, PHLPP1 levels
were unchanged after inhibition of PI3K/Akt in all four lines
derived from glioblastoma but were sensitive to inhibition of
PI3K in the astrocytoma cell lines in which phospho-Akt and
PHLPP1 levels predicted an intact loop (Fig. 1c). These data are
consistent with a model in which Akt-mediated regulation of
PHLPP1 stability is lost in aggressive glioblastomas but not in
less aggressive astrocytomas. Thus, we have identified a subset
of high grade tumors that have lost the negative feedback loop
between PHLPP1 and Akt, implying that this event may be an
important factor in the progression of this disease.
Interestingly, we found that the turnover of PHLPP1 is
noticeably slower in U251 cells (broken loop) compared with
that in SF-268 (intact loop) in which the half-time of PHLPP1
turnover is similar to that previously reported (Fig. 4a)
(44). This suggests that there is a defect in basal PHLPP1 deg-
radation that is independent of agonist-evoked signaling. We
investigated each step in the process of PHLPP1 degradation
and determined that neithermutation of PHLPP1 nor inactiva-
tion of the kinases responsible for preparing it for ubiquitina-
tion is observed in glioblastoma (Fig. 2b). Instead, cellular
fractionation revealed that -TrCP1, the E3-ligase responsible
for targeting PHLPP1 for degradation, is differentially localized
in astrocytomas versus glioblastomas. In astrocytoma cell lines
containing an intact feedback loop, both-TrCP1 and PHLPP1
are primarily located in the cytosol. However, although
PHLPP1 is in the cytosol of glioblastoma cells, -TrCP1 is con-
fined to the nucleus. These data suggest that under normal
circumstances (intact feedback loop), when PHLPP1 is phos-
phorylated by CK1 and GSK-3, it is then bound and ubiquiti-
nated by the SCF-TrCP1 complex, leading to degradation by the
proteasome. However, in glioblastoma, although PHLPP1 is
properly phosphorylated by upstreamkinases, it is spatially seg-
regated from -TrCP1, and thus PHLPP1 can no longer inter-
act with -TrCP1 and is not as readily degraded. Consistent
with this, reintroduction of -TrCP1 to the cytosol of glioblas-
toma cells is sufficient to restore the ability of Akt to control
PHLPP1 levels. Therefore, PHLPP1 levels are not properly reg-
ulated in glioblastoma under basal or agonist-stimulated con-
ditions because of the altered, nuclear localization of -TrCP1.
Curiously, our findings reveal that PHLPP1, although uncou-
pled fromAkt, is actuallymore stable in glioblastoma compared
with astrocytoma. This suggests that loss of the feedback loop
does not modulate PHLPP levels in a manner that could
account for the constitutive activation of Akt, as was our initial
hypothesis. Thus, our work establishes that PHLPP1 levels are
insensitive to PI3K inhibitors in glioblastoma, but a compensat-
ing mechanism stabilizes the protein. Interestingly, analysis of
PHLPP1mRNA levels showed that in amajority of the glioblas-
toma cell lines tested there is significantly less PHLPP1 mRNA
compared with the astrocytoma cell lines. These data explain
why, despite the decreased rate of degradation in glioblastoma,
steady-state levels of PHLPP1 protein are similar to those
detected in the astrocytoma cell lines (Fig. 4) and ultimately
why these cell lines were identified from our screen of the
NCI60. To date little is known about howPHLPP is regulated at
the transcriptional level. -TrCP1 is known to affect the tran-
scription of various proteins through modulation of its sub-
strates, most notably the T-cell specific transcription factor/
lymphoid enhancer binding factor (TCF/LEF), ATF/cAMP-
response element-binding protein (CREB), and NF-B
transcription factors (50–52). Therefore, it is an intriguing pos-
sibility that -TrCP1 could influence both the biosynthesis
(RNA levels) and degradation of PHLPP1. Importantly, our
data reveal that inhibition of the PI3K pathway in glioblastoma,
in contrast to astrocytoma, will not reduce PHLPP1 levels.
Previous reports from both immunohistochemical and over-
expression studies have revealed primarily cytoplasmic local-
ization of-TrCP1 (53–55), consistent with the cytosolic local-
ization of the majority of its substrates. Here, we find that in
healthy human brain, -TrCP1 is localized to the cytosol,
whereas nuclear accumulation is associated with high grade
glioblastoma (Fig. 3). To our knowledge this is the first report to
show that endogenous-TrCP1 is cytosolic in the human brain
andmislocalized to the nucleus in human glioblastoma tumors.
To date we have been unable to establish whether endogenous
Homolog of Slimb(HOS)/-TrCP2, a functionally redundant
-TrCP isoform, is also confined to the nucleus in glioblastoma
due to a lack of suitable reagents. However, given the degrada-
tion of multiple shared substrates of -TrCPs is impaired, it is
clear that if -TrCP2 is cytosolic, it is unable to compensate for
the loss of -TrCP1 in the cytosol. Themechanism responsible
for the nuclear confinement of -TrCP1 in glioblastoma
remains unknown, as there are numerous possible culprits.
-TrCP1 does not contain a nuclear localization signal and,
therefore,must be localized to the nucleus through interactions
with other proteins. It is possible that increased affinity or
abundance of a nuclear protein could sequester -TrCP1 in the
nuclear compartment. In fact, it has been reported that
-TrCP1 is primarily nuclear in some cell types because of con-
stitutive binding to the nuclear phosphoprotein, heterogeneous
nuclear ribonucleoprotein U (hnRNP-U) (56). Recent work has
also shown that differential splicing of -TrCP1 can result in
dramatic changes in cellular localization and biological roles
(57). Our model is consistent with nuclear localization of
-TrCP1 impairing its ability to target its cytosolic substrates
for degradation. Thus, a more thorough exploration of the
mechanisms governing -TrCP localization may be significant
in understanding the activation of signal transduction path-
ways influenced by its substrates.
The finding that -TrCP1 is confined to the nucleus and
cannot properly regulate the cytosolic degradation of sub-
strates is particularly intriguing considering that several of the
proteins -TrCP1 is known to regulate are linked to tumor
progression (40). Here we demonstrate that the cytosolic pool
of -catenin is degraded at a slower rate in glioblastoma cell
lineswhere-TrCP1 is confined to the nucleus (Fig. 4). There is
precedent for the induction of -catenin in the progression of
tumors, specifically those of the CNS. Immunohistochemical
studies comparing-catenin levels in glioma patient samples to
those in normal brain tissue reveal that -catenin levels are
higher in glioma samples, correlating with poor patient prog-
nosis and outcome, yet relative mRNA levels remain un-
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changed, supporting a defect in protein degradation (49, 58).
Another study of glioblastoma patient samples reported
intense, homogenous staining of -catenin in the cytoplasm of
81% (26/32) of samples (59). Additionally, a study of 45 astro-
cytic gliomas showed a correlation between increased expres-
sion of -catenin and ascending order of the tumor grade (60).
Over 80% of glioblastoma (9/11) displayed high immunoreac-
tivity for -catenin, yet only two of these stained positively for
nuclear accumulation, indicating that a majority of the cyto-
plasmic -catenin is not being properly degraded. It is also of
note thatmutations of-catenin thatwould render it refractory
to degradation are very rare in brain tumors, suggesting another
aberration is responsible for accumulation of -catenin in
tumorigenesis (61, 62). Taken together with our findings,
altered localization of -TrCP1 in glioblastoma is potentially
responsible for the unusually high levels of -catenin observed
in high grade glioma patient samples. Therefore, in addition to
loss of PHLPP1 regulation, the stabilization of oncogenic fac-
tors arising fromnuclear localization of-TrCP1may be favor-
ably selected for in late stage tumors.
In summary, we have identified a subset of CNS tumors that
display a distinct cellular localization of -TrCP1. Our finding
that the cellular localization of -TrCP1 is altered in glioblas-
toma contributes to the dysregulation of two signal transduc-
tion pathways that are critical in tumorigenesis.Mislocalization
of -TrCP1 in glioblastoma not only impairs the ability of Akt
to regulate PHLPP1 stability (rendering PHLPP levels insensi-
tive to inhibition of the PI3K pathway) but also provides a novel
mechanism for the amplification of-catenin often observed in
this disease.
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